Cargando…

Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients

PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic b...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Crystal, Barlev, Arie, Worrall, Jodie, Duff, Steve, Beckerman, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782278/
https://www.ncbi.nlm.nih.gov/pubmed/33489434
http://dx.doi.org/10.1080/21556660.2020.1854561
_version_ 1783631864732319744
author Watson, Crystal
Barlev, Arie
Worrall, Jodie
Duff, Steve
Beckerman, Rachel
author_facet Watson, Crystal
Barlev, Arie
Worrall, Jodie
Duff, Steve
Beckerman, Rachel
author_sort Watson, Crystal
collection PubMed
description PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients. DESIGN: This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies. RESULTS: PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations. CONCLUSIONS: Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden.
format Online
Article
Text
id pubmed-7782278
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-77822782021-01-21 Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients Watson, Crystal Barlev, Arie Worrall, Jodie Duff, Steve Beckerman, Rachel J Drug Assess Immunology PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients. DESIGN: This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies. RESULTS: PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations. CONCLUSIONS: Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden. Taylor & Francis 2020-12-24 /pmc/articles/PMC7782278/ /pubmed/33489434 http://dx.doi.org/10.1080/21556660.2020.1854561 Text en © 2020 Atara Biotherapeutics. Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Immunology
Watson, Crystal
Barlev, Arie
Worrall, Jodie
Duff, Steve
Beckerman, Rachel
Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title_full Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title_fullStr Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title_full_unstemmed Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title_short Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
title_sort exploring the burden of short-term chop chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782278/
https://www.ncbi.nlm.nih.gov/pubmed/33489434
http://dx.doi.org/10.1080/21556660.2020.1854561
work_keys_str_mv AT watsoncrystal exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients
AT barlevarie exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients
AT worralljodie exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients
AT duffsteve exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients
AT beckermanrachel exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients